749 results on '"Rueda, Bo"'
Search Results
2. Author Correction: Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair
3. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
4. Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair
5. Structural basis for antibody recognition of the proximal MUC16 ectodomain
6. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma
7. High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options
8. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells
9. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway
10. Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development
11. Reprogramming of ovarian granulosa cells by YAP1 leads to development of high-grade cancer with mesenchymal lineage and serous features
12. Abstract A113: Extracellular vesicles derived from enriched ovarian cancer stem cell fractions promote stem like properties in the more vulnerable tumor cell populations
13. Abstract B109: Uncovering novel vulnerabilities in ovarian cancer by studying cell death in neoplastic transformation
14. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
15. CABLES1 Deficiency Impairs Quiescence and Stress Responses of Hematopoietic Stem Cells in Intrinsic and Extrinsic Manners
16. A Human Papillomavirus-Independent Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis
17. Supplementary Figure 6 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
18. Supplementary Figure 24 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
19. Supplementary Figure 5 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
20. Supplementary Figure 17 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
21. Supplementary Tables S1-S12 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
22. Supplementary Figure 9 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
23. Supplementary Figure 7 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
24. Supplementary Data 1 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
25. Data from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
26. Supplementary Figure 4 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
27. Supplementary Data 2 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
28. Supplementary Figure 8 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
29. Supplementary Figure 3 from Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
30. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
31. Endometrial Cancer Is a Receptor-Mediated Target for Mullerian Inhibiting Substance
32. Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker
33. Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity
34. Inaugurating High‐Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer Detection (Adv. Sci. 27/2023)
35. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors
36. Transient commensal clonal interactions can drive tumor metastasis
37. The Epidemiology and Genetics of Uterine Leiomyoma
38. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
39. YAP1‐LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis
40. Abstract 5731: Apoptosis Inducing Agent 1 enhances cancer therapy-induced apoptosis by direct interaction with BAX and BAK
41. Abstract 6161: Targeting endogenous and therapy-induced dependence on BCL-XL in high grade serous ovarian carcinoma
42. Abstract 2438: Loss of galectin 3 reveals its potential roles in the aggressive pathology of uterine serous carcinoma
43. Supplementary Figures from PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells
44. Supplementary Table S1 from PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells
45. Data from PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells
46. Supplementary Data from PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells
47. Supplementary Figure Legends from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
48. Data from Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
49. Supplementary Table 4 from Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
50. Supplementary Table 5 from Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.